From the Departments of Diagnostic Imaging, Molecular Imaging, Interventional Radiology, and Radiation Therapy University Hospital "Tor Vergata", Rome, Italy.
Diagn Interv Radiol. 2014 May-Jun;20(3):267-70. doi: 10.5152/dir.2013.13408.
We describe our preliminary experience with percutaneous renal denervation in end-stage renal disease patients with resistant hypertension and challenging anatomy, in terms of the feasibility, safety, and efficacy of this procedure. Four patients with end-stage renal disease patients with resistant hypertension (mean hemodialysis time, 2.3 years) who had been taking at least four antihypertensive medications underwent percutaneous renal denervation. Renal artery eligibility included the absence of prior renal artery interventions, vessel stenosis <70%, or extended calcifications (more than 30% of the vessel circumference). No cut off values of vessel diameter were used. All patients were successfully treated with no intra- or postprocedural complications, and all showed 24-hour ambulatory blood pressure reduction at the 12-month follow-up. Percutaneous renal denervation is a feasible approach for end-stage renal disease patients with resistant hypertension with encouraging short-term preliminary results in terms of procedural efficacy and safety.
我们描述了我们在终末期肾病伴难治性高血压和具有挑战性解剖结构的患者中进行经皮肾动脉去神经术的初步经验，主要涉及该手术的可行性、安全性和疗效。4 名终末期肾病伴难治性高血压（平均血液透析时间 2.3 年）的患者接受了经皮肾动脉去神经术。肾动脉入选标准包括无既往肾动脉介入治疗、血管狭窄<70%或广泛钙化（超过血管周长的 30%）。未使用血管直径的截断值。所有患者均成功接受治疗，无术中或术后并发症，所有患者在 12 个月随访时均显示 24 小时动态血压降低。经皮肾动脉去神经术对于终末期肾病伴难治性高血压的患者是一种可行的方法，在操作疗效和安全性方面具有令人鼓舞的短期初步结果。
